Zura Bio Limited - ZURA STOCK NEWS

Zura Bio (Nasdaq: ZURA) has submitted a protocol to the FDA for a Phase 2 study of tibulizumab, a dual-pathway antibody targeting IL-17A and BAFF, for treating systemic sclerosis in adults. The planned double-blind, randomized study will evaluate safety, tolerability, and efficacy in approximately 80 participants with early diffuse cutaneous systemic sclerosis. The trial aims to demonstrate improvements in skin and lung symptoms and includes an open-label extension. Expected to begin in Q4 2024, the company has already submitted an Orphan Drug Designation request to the FDA.

Zura Bio (NASDAQ: ZURA) reported Q3 2024 financial results with a net loss of $22.9 million ($0.26 per share), compared to $8.3 million ($0.18 per share) in Q3 2023. The company maintains a strong cash position of $188.2 million, expected to fund operations through 2027. Research and development expenses increased to $6.0 million, while general and administrative expenses rose to $13.3 million.

The company plans to initiate Phase 2 trials for tibulizumab in systemic sclerosis (Q4 2024) and hidradenitis suppurativa (Q2 2025). An Orphan Drug Designation application was submitted to the FDA for systemic sclerosis treatment.

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in two major investor conferences this November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 1:00 p.m. ET in Boston, and will host investor meetings at the Jefferies London Healthcare Conference on November 21, 2024, in London. Webcasts and replays will be available on Zura Bio's website's News & Events page for at least 30 days after the events.

Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced its participation in three upcoming investor conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 11:30 a.m. ET, the Stifel Immunology and Inflammation Virtual Summit on September 17 at 12:00 p.m. ET, and the Cantor Global Healthcare Conference on September 17 at 2:30 p.m. ET.

Zura Bio's senior leadership team will host investor meetings at these events, with the Stifel summit being virtual. Live webcasts and replays of the presentations will be available on the company's website for at least 30 days following each event.

Zura Bio (Nasdaq: ZURA) reported Q2 2024 financial results and business highlights. Key points include:

• Presented tibulizumab data at EULAR 2024, showing potential for dual inhibition of IL-17A and BAFF in autoimmune diseases
• Plans to initiate Phase 2 studies for tibulizumab in systemic sclerosis (Q4 2024) and hidradenitis suppurativa (Q2 2025)
• Appointed Robert Lisicki as CEO and formed Scientific Advisory Board
• Cash position of $188.4 million as of June 30, 2024, expected to support operations through 2027
• Q2 2024 net loss of $12.7 million ($0.17 per share)
• R&D expenses decreased to $5.5 million, while G&A expenses increased to $6.2 million

Zura Bio (Nasdaq: ZURA) has completed its exchange offer and consent solicitation for outstanding public and private placement warrants. The company issued 3,235,184 ordinary shares in exchange for tendered IPO warrants. Zura Bio will exercise its right to exchange all remaining untendered IPO warrants at a ratio of 0.27 Class A ordinary shares per warrant on August 27, 2024. As a result, no IPO warrants will remain outstanding, leading to their suspension from trading on Nasdaq as of August 26, 2024, and subsequent delisting. The company's Class A ordinary shares will continue to trade on Nasdaq under the symbol 'ZURA'.

Zura Bio (Nasdaq: ZURA) has announced the expiration and results of its exchange offer and consent solicitation for outstanding public and private placement warrants. 97.2% of public warrants and 69.0% of private placement warrants were validly tendered. The company expects to accept all validly tendered IPO warrants for exchange and settlement by August 12, 2024. The consent solicitation received approval for the Warrant Amendment, allowing Zura Bio to require conversion of remaining warrants at a 10% lower ratio than the exchange offer. Zura Bio plans to execute the Warrant Amendment and exercise its right to exchange all remaining untendered IPO warrants, after which no IPO warrants will remain outstanding.

Zura Bio, a clinical-stage immunology company (NASDAQ: ZURA), has announced an exchange offer and consent solicitation for its public and private placement warrants issued during its initial public offering. The company aims to simplify its capital structure and reduce potential dilution by offering 0.30 Class A ordinary shares for each outstanding IPO warrant. This exchange offer could result in issuing up to 3,842,999 new shares, an approximate 6% increase in outstanding shares. Concurrently, Zura Bio seeks consents to amend the warrant agreement to enforce the exchange of all remaining warrants at 0.27 shares per warrant if the offer succeeds. The offer period ends on August 8, 2024. Parties holding 40.7% of public warrants and 65.3% of private placement warrants have already agreed to tender their warrants.

Zura Bio presented data on tibulizumab (ZB-106) at EULAR 2024, demonstrating promising results in treating Sjogren's syndrome and rheumatoid arthritis (RA). The Phase 1 study showed tibulizumab was well-tolerated and effective in neutralizing IL-17A and BAFF, reducing B cell counts and modulating inflammatory mediators in 25 participants. Preclinical data in a RA mouse model indicated significant reductions in disease scores and inflammation when both IL-17A and BAFF were inhibited. The studies suggest tibulizumab's potential as a dual-pathway treatment for autoimmune diseases.